Anna K. Winge-Main, MD

MD, Oslo University Hospital, Dep. of Oncology. Clinical oncologist and research melanoma. Views are my own.

[Society for Immunotherapy of Cancer @sitcancer]

SITC's IO Resistance Committee published consensus definitions of PD-1/L1 resistance to facilitate clinical trial harmonization. Dr. Megan Othus is presenting an abstract at #ASCO25 with more information — visit poster 303 today, June 2, from 1:30–4:30 pm CT!

[Anna K. Winge-Main, MD @AKWingeMain]

Bridging neoadjuvant knowledge from melanoma into GBM treatment and beyond. 👏🏻 @ProfGLongMIA and colleagues

[Professor Georgina Long AO (Bluesky @gvlongphdmd) @ProfGLongMIA]

https://t.co/ZwgGhNqwqN
This #science is exciting! It shows the power of vision & action in an inspired team. Within 12 days of 1st dose of triple combination #immunotherapy in #glioblastoma 1) >8x more immune cells in the #GBM, 2) immune cells were newly activated & 3) PD1 drug bound to immune cells in the GBM. This took extensive drug development experience, toxicity management & #clinicaltrial expertise, skilled neurosurgeon @Dr_Brindha & nursing, support from neuro-oncology team & incredible scientists includ. my co-lead author @HelenRizos. I drafted a #clinicaltrial design, secured the drugs within 4 months for international trial. With strong collaboration & agile teams there was a seamless handover to ⁦@BrainCancerCtr⁩ ⁦@WEHI_research⁩ ⁦@PeterMacCC⁩ spearheaded by @whittlejim
@Sydney_Uni @MelanomaAus @Science_Academy @FulbrightAUS @ausoftheyear @AAHMS_health @smh @Macquarie_Uni @ASCO @sitcancer @AACR @myESMO @FulbrightAUS @smh

[Anna K. Winge-Main, MD @AKWingeMain]

Ipilimumab + nivolumab still treatment of choice for our patients with asymptomatic bran mets #ABCstudy

[Omid Hamid MD @OmidHamidMD]

7 year data with ipilimumab & #nivolumab #brainmetastases in #melanoma @TheLancet setting standard and safety with radiation
- maintains efficacy, standard of care for patients with melanoma brain metastasis. @ProfGLongMIA @MattCarlino
https://t.co/TRRcyAsmA3

[Ashwin Rajenesh MD @ashwinrajenesh]

"Is there a doctor on the plane?"✈️🩺
Responding to in-flight medical emergencies.
#MedTwitter

[NEJM @NEJM]

Original Article: Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma (CheckMate 067) https://t.co/dcXkj4NQw7

#ESMO24 | @myESMO

[Icro Meattini @Icro_Meattini]

Impact of Exercise on Cancer Recurrence and Survival #ESMO24

@OncoAlert #OncoAlert

[Omid Hamid MD @OmidHamidMD]

Jeffrey S Weber's life is a testament to mentorship, patient care, sacrifice, leadership. Thank you @jitcancer for allowing us to share a glimpse of this giant.
https://t.co/IPMcAbPYj2
@jasonlukemd @BernardAFox @MoffittNews @uscnorris @nyulangone @theNCI @ASCO @CureMelanoma @MelanomaReAlli

[NEJM @NEJM]

Presented at #ESMO24:

Among patients with advanced melanoma, median overall survival was 72 months with nivolumab plus ipilimumab and was 37 months with nivolumab alone, as compared with 20 months with ipilimumab alone.

Full CheckMate 067 trial results: https://t.co/dcXkj4NQw7

[Allison Betof, MD, PhD, FASCO @DrBetofMDPhD]

NADINA update from @MinkeLucas: DMFS data🚨 18 mo DMFS 85.7 vs 62.4%. Patterns of distant recurrence shown. MPR 60.8%. pCR 98.2% 18 month DMFS. The DMFS data are a key addition to the field. Ongoing clear superiority of neoadjuvant ipi1/nivo3 over adjuvant PD-1. Further evidence that NADINA is a new standard of care. #ESMO24 @OncoAlert

[Allison Betof, MD, PhD, FASCO @DrBetofMDPhD]

We lost a legend today. Jeff meant so much to the fields of melanoma and immuno-oncology. We were fortunate to learn from him and share the fruits of his labor with our patients. May his memory be a blessing.

[Nico Gagelmann @NicoGagelmann]

Tumor immunology, simplified😅

[Society for Immunotherapy of Cancer @sitcancer]

Great presentation at #ASCO24 from Dr. Christian U. Blank of @NKI_nl on Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial. #Immunoptherapy #SITC24 #immunotherapy

[ASCO @ASCO]

More from the #ASCO24 Plenary Session: NADINA results: Neoadjuvant Ipi + Nivo w/ the possibility of additional adjuvant therapy yields superior EFS compared w/ adjuvant Nivo alone in pts w/ macroscopic stage III #melanoma: https://t.co/IEdyN7mpVv #ASCODailyNews #melsm